Why Do So Many HealthTech Startups Stall After Early Traction with Dirk Schapeler Titelbild

Why Do So Many HealthTech Startups Stall After Early Traction with Dirk Schapeler

Why Do So Many HealthTech Startups Stall After Early Traction with Dirk Schapeler

Jetzt kostenlos hören, ohne Abo

Details anzeigen

Über diesen Titel

 Why do so many healthtech startups gain early traction… and then suddenly stall?It’s usually not the tech. It’s not the vision. And it’s rarely a lack of effort.In this episode, I’m joined by Dirk Schapeler, President of Niterra Ventures (https://www.niterraventures.com/) — the venture arm of Niterra, a $5B Japanese technology company operating globally across automotive, medical, and industrial products. Dirk also serves as a board member at Arcondis Group, where he supports innovation strategy and global expansion. At HLTH, I sat down with Dirk to talk about what actually determines whether a healthcare company survives long enough to matter—especially in regulated, capital-intensive spaces like medtech, remote care, and diagnostics.If you’ve proven demand but growth feels harder than it should, this conversation is for you.This wasn’t a hype-filled conversation about AI buzzwords.It was a grounded discussion about patience, leadership evolution, and why healthcare scale is less about speed and more about systems, people, and partnerships.If you’re building in healthcare and wondering why momentum feels harder than it should… this episode will hit close to home.🎧 In this episode, you’ll learn:Why some of the most powerful healthcare innovations come from outside healthcareWhat investors really look for when regulation and reimbursement are unavoidableHow to think about unmet need vs. “interesting” ideas that won’t scaleWhy leadership evolution, not just vision, determines whether companies break through growth ceilingsHow combining technologies and partners creates defensibility most startups missWhat founders underestimate about human capital in regulated marketsEpisode Timeline:00:00:00 – Why health tech stalls after early wins00:04:04 – Why Japanese innovation looks at the U.S. market00:07:02 – Cold plasma and the future of wound care00:09:40 – Why wound care hasn’t changed in decades00:11:27 – Combining therapies, not selling tools00:13:05 – What investors really look for00:15:31 – Patience, quality, and long-term thinking00:18:08 – When founders hit the scaling wall00:21:09 – Power of global collaboration00:25:00 – The hard truth about regulated healthcare00:27:03 – How to connect with Niterra Ventures🎧 Related Episodes You’ll LoveWhy Most HealthTech Solutions Fail: The Hidden Gap Between Innovation and Implementation – This episode digs into the common pitfalls that healthtech founders face (particularly in scaling and market fit).Is Your Startup Built on Swiss Cheese with George Pappas – A strong fit because it explores structural weaknesses in startups (teams, roles, funding) that align directly with what we unpacked with MyPhuong.What Traction Signals Investors Say Yes To – Especially relevant for founders looking for their first backers, this episode zeroes in on what investors are actually looking for.Want to Keep Growing Without Losing Clients?Here are 3 ways we can help you today:Be a Featured Guest on the Provider’s EdgeHave traction and a story to share? Apply to join us on the show: PulsePointPath.com/Call-Sabrina Make Your Pitch Investor-ReadySend us your draft and let me rewrite it so it becomes a funding magnet 👉 PitchToYes.com 🚀 Get in Front of Investors Who Already Want What You’ve BuiltNot every investor needs a white paper; they need a reason to believe.Leveraging third-party validation is one of the easiest ways to create trust. Nominate your company at 👉 HealthTechImpactAward.com before March 1, 2026 to win one of the six awards in digital health, diagnostics, biotech, mental health, women's health, and medical devices.
Noch keine Rezensionen vorhanden